Drugs / CV09050101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05938387 | Jun 2023 → Feb 2026 | glioblastoma | CureVac | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CV09050101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05938387 ↗ |
| Known as | CVGBM | “CV09050101 mRNA vaccine (CVGBM) 12 μg” NCT05938387 ↗ |